Moxistad
On the Bulgarian pack: Моксистад 400 mg филмирани таблетки
400 mg · film-coated tablets
- Prescription only
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Moxifloxacin
- Made by
- Stada Arzneimittel AG
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet read the official leaflet for this product. The exact uses and dose are in the leaflet inside the pack. Open the official leaflet
How it works
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (moxifloxacin). It describes the substance, not this Bulgarian product — its uses and doses can differ.
Moxifloxacin is a member of the fluoroquinolone class of antibacterial agents [see Microbiology ( 12.4 )].
Approximately 52% of an oral or intravenous dose of moxifloxacin is metabolized via glucuronide and sulfate conjugation.
The sulfate conjugate (M1) accounts for approximately 38% of the dose, and is eliminated primarily in the feces.
Co-administration with a high fat meal (that is, 500 calories from fat) does not affect the absorption of moxifloxacin.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-03-17
Safety of the active substance
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (moxifloxacin). It describes the substance, not this Bulgarian product — its uses and doses can differ.
Fluoroquinolones, including moxifloxacin tablets, may exacerbate muscle weakness in patients with myasthenia gravis.
- Moxifloxacin tablets are contraindicated in persons with a history of hypersensitivity to moxifloxacin or any member of the quinolone class of antibacterials [see Warnings and Precautions ( 5.8 )].
- Known hypersensitivity to moxifloxacin tablets or other quinolones ( 4, 5.8 )
The most common adverse reactions (>0.3%) leading to discontinuation with the 400 mg oral doses were nausea, diarrhea, dizziness, and vomiting.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States16 matching products
Spain19 matching products
- ABIOX 400 mg · comprimido recubierto con película
- ACTIRA 400 mg · comprimido recubierto con película
- ERELAN 400 mg · comprimido recubierto con película
- MOXIFLOXACINO ACCORD 400 mg · comprimido recubierto con película
- MOXIFLOXACINO AUROVITAS 400 mg · comprimido recubierto con película
- MOXIFLOXACINO BLUEPHARMA 400 mg · comprimido recubierto con película
- MOXIFLOXACINO CINFA 400 mg · comprimido recubierto con película
- MOXIFLOXACINO KERN PHARMA 400 mg · comprimido recubierto con película
Canada13 matching products
Netherlands5 matching products
- Erelan 400 mg filmomhulde tabletten 400 mg · filmomhulde tablet
- Moxifloxacine Aurobindo 400 mg 400 mg · filmomhulde tablet
- Moxifloxacine MSN 400 mg filmomhulde tabletten 400 mg · filmomhulde tablet
- Moxifloxacine Sandoz 400 mg 400 mg · filmomhulde tablet
- Moxifloxacine Teva 400 mg 400 mg · filmomhulde tablet
SwitzerlandNo exact match for this strength and form
Details
| Made by | Stada Arzneimittel AG · Germany |
|---|---|
| Active substance | Moxifloxacin |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Strength | 400 mg |
| Form | film-coated tablets |
| Pack sizes | 5 · 7 · 10 · 25 · 50 |
| Classification | J01MA14 · Antibiotics, antivirals and antifungals taken into the body |
| Name in the register | Моксистад 400 mg филмирани таблетки |
| Reg. no. | 20150204 |
Source: Bulgarian Drug Agency register · 2026-08-01 · not reviewed by a clinician
Източник: Изпълнителна агенция по лекарствата (ИАЛ). The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.